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Abstract
Multidrug resistance (MDR) remains a dominant impediment to curative cancer chemotherapy. Efflux transporters of the
ATP-binding cassette (ABC) superfamily including ABCG2, ABCB1 and ABCC1 mediate MDR to multiple structurally and
functionally distinct antitumor agents. Recently we identified a novel mechanism of MDR in which ABCG2-rich extracellular
vesicles (EVs) form in between attached neighbor breast cancer cells and highly concentrate various chemotherapeutics in
an ABCG2-dependent manner, thereby sequestering them away from their intracellular targets. Hence, development of
novel strategies to overcome MDR modalities is a major goal of cancer research. Towards this end, we here developed a
novel approach to selectively target and kill MDR cancer cells. We show that illumination of EVs that accumulated
photosensitive cytotoxic drugs including imidazoacridinones (IAs) and topotecan resulted in intravesicular formation of
reactive oxygen species (ROS) and severe damage to the EVs membrane that is shared by EVs-forming cells, thereby leading
to tumor cell lysis and the overcoming of MDR. Furthermore, consistent with the weak base nature of IAs, MDR cells that are
devoid of EVs but contained an increased number of lysosomes, highly accumulated IAs in lysosomes and upon
photosensitization were efficiently killed via ROS-dependent lysosomal rupture. Combining targeted lysis of IAs-loaded EVs
and lysosomes elicited a synergistic cytotoxic effect resulting in MDR reversal. In contrast, topotecan, a bona fide transport
substrate of ABCG2, accumulated exclusively in EVs of MDR cells but was neither detected in lysosomes of normal breast
epithelial cells nor in non-MDR breast cancer cells. This exclusive accumulation in EVs enhanced the selectivity of the
cytotoxic effect exerted by photodynamic therapy to MDR cells without harming normal cells. Moreover, lysosomal
alkalinization with bafilomycin A1 abrogated lysosomal accumulation of IAs, consequently preventing lysosomal
photodestruction of normal breast epithelial cells. Thus, MDR modalities including ABCG2-dependent drug sequestration
within EVs can be rationally converted to a pharmacologically lethal Trojan horse to selectively eradicate MDR cancer cells.
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Introduction
A primary hindrance to successful cancer therapy remains the
frequent emergence of drug resistance to structurally and
functionally unrelated anticancer drugs, a phenomenon known
as multidrug resistance (MDR) [1,2,3,4,5,6]. Transporters of the
ATP-Binding Cassette (ABC) superfamily including ABCB1 (P-
gp), ABCC1 (MRP1) and ABCG2 (BCRP), function as ATP-
dependent MDR efflux transporters. These efflux pumps form a
unique defense network against multiple chemotherapeutic drugs
as well as endogenous and exogenous cellular toxicants. Recently,
we identified a novel modality of chemoresistance to multiple
anticancer drugs mediated by ABCG2-rich extracellular vesicles
(EVs) formed between neighbor carcinoma cells. Although we
initially identified and characterized EVs in mitoxantrone-resistant
breast cancer cells [7,8], drug sequestration by EVs was also found
in other tumor cell lines of distinct tissue origin including non-
small lung cancer [9] and gastric carcinoma cells [8]. Overex-
pression of ABCG2 in the membrane of EVs resulted in cellular
resistance to several cytotoxic drugs including mitoxantrone [10],
topotecan and imidazoacridinones (IAs) [8], due to their dramatic
sequestration and concentration in the lumen of EVs. Inhibition of
ABCG2 transport activity with the specific transport inhibitors
Ko143 or fumitremorgin C (FTC) abolished intravesicular
accumulation, thereby resulting in restoration of drug sensitivity.
We further found EVs to be apically localized, sealed structures,
reinforced by an actin-based cytoskeleton and secluded from the
extracellular milieu by the tight junction proteins occludin and
ZO-1. Moreover, Ezrin-Radixin-Moesin (ERM) protein complex
selectively localized to the border of the EVs membrane,
suggesting a key role for ERM in MDR pump tethering to the
actin cytoskeleton [8].
IAs are cytotoxic fluorochromes with hydrophobic weak base
properties which have shown significant clinical activity against
colorectal and breast cancers [11]. IAs bearing a hydroxyl group at
one of the R1, R2, R3 positions in the proximal IA ring, including
C-1371, C-1492 and C-1309 were recognized as ABCG2
transport substrates and were actively extruded from ABCG2-
overexpressing MDR cells [12]. In contrast, IAs lacking a hydroxyl
group such as C-1266 and C-1375 were not recognized by the
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to mitoxantrone which is an established topoisomerase II inhibitor
[13], hence suggesting similar cellular targets for cytotoxicity.
Topotecan, a water-soluble derivative of camptothecin, is a
natural chromophoric anticancer drug that elicits its cytotoxic
activity by stabilizing a covalent topoisomerase I-DNA complex,
thereby inflicting a hindrance to the progression of the DNA
replication fork with subsequent formation of lethal DNA adducts
[14]. Topotecan is an established ABCG2 transport substrate
[15,16,17] and is currently approved for the treatment of ovarian
cancer and small-cell lung cancer. We have previously shown that
topotecan highly accumulates in EVs in an ABCG2-dependent
manner, thereby resulting in 25-fold resistance in MCF-7/MR
cells relatively to their parental MCF-7 cells [8].
Photodynamic therapy (PDT), a treatment modality for cancer
and non-malignant disorders, involves administration of a
photosensitizer and an accurate delivery of light to the tumor
mass or the target tissue. Once excited by light at an appropriate
wavelength, the photosensitizer releases energy that is transferred
to molecular oxygen thereby forming reactive oxygen species
(ROS), which elicit a potent cytotoxic effect [18,19]. Taking
advantage of the inherent fluorescent properties of IAs we show
here that IAs which are ABCG2 substrates highly concentrate
within EVs in an ABCG2-dependent manner, similarly to
topotecan. Moreover, photoexcitation of these photosensitizer-
loaded EVs resulted in the rapid rupture of the membrane of EVs,
a process that was mediated by ROS [20]. Moreover, since the
membrane of EVs is an integral part of the plasma membrane,
EVs-forming tumor cells were efficiently killed due to rapid cell
lysis. In contrast, IAs which are not ABCG2 substrates and cannot
be sequestered within EVs, highly accumulated in lysosomes due
to their hydrophobic weak base nature. Upon illumination, rapid
production of ROS resulted in lysosomal photodestruction, spill of
multiple lysosomal hydrolytic enzymes into the cytoplasm, thereby
leading to rapid cell death. In contradistinction to IAs, topotecan
was neither detected in lysosomes of cancer cells (MCF-7) nor in
lysosomes of normal breast epithelial cells (MCF-10A), but
accumulated exclusively in ABCG2-rich EVs of MDR cancer
cells (MCF-7/MR). This exclusive concentration within EVs
allowed for the selective destruction of MDR cells without
harming normal cells; this selective cytotoxic effect was due to
the lack of topotecan accumulation in lysosomes and hence the
lack of lysosomal photodestruction in normal cells. Collectively,
our current findings establish that ABCG2-mediated sequestration
and accumulation of certain photosensitizers within EVs markedly
enhances the selectivity and the cytotoxic activity exerted by PDT,
thereby rendering these EVs a pharmacological photosensitive
lethal Trojan horse for the future overcoming of MDR cancers.
Results
IAs are highly concentrated in ABCG2-rich EVs formed in
MCF-7/MR cells
Recently we have shown that a class of cytotoxic drugs known as
IAs including C-1371, C-1492, C-1309 and C-1336 are bona fide
transport substrates of ABCG2 [12]. We therefore hypothesized
that IAs may be actively sequestered and concentrated within
ABCG2-rich EVs. Taking advantage of the photosensitizer nature
of IAs we examined their intravesicular accumulation in
mitoxantrone-resistant breast cancer cells (MCF-7/MR) that
overexpress ABCG2 exclusively at the membrane of EVs. MCF-
7/MR cells were cultured in riboflavin-deficient medium to avoid
riboflavin autofluorescence [9] and incubated with various IAs
which are established ABCG2 transport substrates [12]. We found
that these IAs were specifically concentrated within ABCG2-rich
EVs (Figure 1A); sequestration of IAs in EVs was mediated by
ABCG2, as it was abolished by the specific ABCG2 transport
inhibitor FTC (Figure 1B). Moreover, MCF-7/MR cells
displayed 7-fold resistance to C-1371, a representative IA; this
resistance was fully reversed by FTC (Figure 1C).
Photosensitization of C-1371-accumulating EVs results in
rapid destruction of EVs
Compartmentalization of IAs in EVs significantly enhanced
MCF-7/MR resistance to these drugs [8]. Thus, based on the
fluorochrome nature of IAs, we examined whether a PDT
approach could overcome the ABCG2-dependent MDR to IAs.
To this end, we first determined whether photodestruction of the
membrane of EVs occurs in EVs that previously accumulated a
photosensitizer IA. MCF-7/MR cells were exposed to C-1371
(10 mM), a representative ABCG2 transport substrate [12], to
allow for its accumulation within EVs, following which cells were
illuminated (excitation 470627; emission 512620 and 630698).
Consistently, EVs highly concentrated C-1371, thereby resulting
in increased luminal green fluorescence (Figure 2A, a–c).
Interestingly, constant exposure of these MDR cells to light for
10 min resulted in a gradual decrease in the fluorescence of EVs
and a simultaneous increase in nuclear fluorescence in EVs-
forming cells (Figure 2A, d–f and Movie S1). Moreover, we
noted that the oval structure of EVs was severely damaged and
deformed, resulting in non-continuous structures with hollow
centers; this suggested that exposure to light inflicts severe damage
to the membrane of EVs which is shared by EVs-forming cells.
Specifically, following illumination, the membrane of EVs
ruptured and collapsed, thereby forming multiple small intrave-
sicular structures (MSIS) which were entrapped within the
damaged cytoskeletal structure enforcing EVs (arrows in
Figure 2B). Similar results were obtained with ABCG2-
overexpressing flavopiridol-resistant breast cancer cells (MCF-7/
FLV1000) which differ from MCF-7/MR cells in their subcellular
localization of ABCG2 and frequency of EVs formation ([8] and
Figure S1A). Exposure of MCF-7/FLV1000 cells to C-1371
resulted in its intravesicular accumulation; illumination of these
cells induced the rupture of the EVs membrane, reduction in the
volume of EVs and gradual leakage of IAs to the cytoplasm,
followed by 1371 intercalation into nuclear DNA, reflected in the
appearance of intensely green fluorescent nuclei (Figure S1 and
Movie S2).
Immunofluorescence studies of EVs prior to and
following photodestruction
To characterize the fate of the EVs structure and the intactness
of their membrane after illumination, we next studied the structure
of C-1371-accumulating EVs after photoexcitation using estab-
lished EVs membrane markers including ABCG2, ERM and ZO-
1. To induce photodestruction of EVs, MCF-7/MR cells
harboring C-1371-loaded EVs were first illuminated, fixed and
co-stained with antibodies to the established vesicular markers
ABCG2 as well as ZO-1, a representative tight junction (TJ)-
associated protein that cross-links TJs to the actin-cytoskeleton
[21,22] (Figure 3), or with antibodies to ABCG2 and the ERM
protein complex (Figure 4). ERM proteins are closely related
polypeptides linking actin microfilaments to the plasma membrane
either directly via binding to the cytoplasmic tail of transmem-
brane proteins, or indirectly through scaffold proteins attached to
membrane proteins [23]. We have previously identified the ERM
complex as a structural marker of EVs as it was selectively targeted
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(Figure 4E–H and [8]). Consistent with our results, we observed a
differential compartmentalization of C-1371 prior to and following
illumination. Specifically, IAs were highly concentrated in EVs
(Figure 3A), however upon photoexcitation, IAs leaked out of
EVs as the membrane of EVs lysed due to the formation of
deleterious ROS including singlet oxygen and hydrogen peroxide
[20], resulting in fluorescent nuclei due to DNA-intercalated IAs;
clearly, the markedly damaged EVs were free of IAs (Figure 3D
a–d and Figure 4A–D). Moreover, in agreement with our above
findings (Figure 2), immunofluorescence studies revealed that
after illumination, the oval-shaped membrane of EVs ruptured,
thereby forming rapidly sealing multiple small vesicular structures
termed MSIS which were entrapped within the lumen of the
remaining cytoskeletal structure of the highly damaged EVs. Upon
rupture of the EVs membrane, proteins associated with the EVs
membrane including ABCG2 (Figure 3D, b) and ERM
(Figure 4C) remained adsorbed to the perimeter of the
cytoskeletal structure of EVs as well as were present in the
membrane of MSIS. Under physiological conditions, TJ proteins
surround ABCG2-rich EVs, hence forming intense ring structures
precisely at the border of EVs-forming cells, thereby sealing the
EVs to the outer environment (Figure 3d–h; and [8]).
Interestingly, following photodestruction of EVs, ZO-1 was still
visible at cell-cell attachment zones surrounding the EVs, similarly
to non-illuminated cells (Figure 3D e–h); albeit, an intense
immunofluorescent signal was also observed in the membrane of
MSIS that formed after the rupture of EVs following illumination
(Figure 3D a–d). IA-accumulating, non-illuminated cells, served
as controls to highlight the initial morphology of EVs as well as
protein localization (Figure 3D e–h and Figure 4E–H).
Dynamics of sub-cellular accumulation of non-ABCG2
substrate IAs and lysosomal photodestruction
Incubation of MCF-7/MR cells with IAs which are not ABCG2
transport substrates including C-1266 [12], resulted in EVs that
were devoid of IA fluorescence, but displayed intense lysosomal
fluorescence (Figure 5A). Accordingly, pulse exposure of C-1266-
rich lysosomes to microscope light resulted in an instantaneous
lysosomal rupture with disappearance of fluorescent lysosomes,
Figure 1. Inhibition of cell growth by IAs and their accumulation in EVs. (A) MCF-7/MR cells were seeded in 6-well dishes (2610
4cells/well;
2 ml medium/well) containing glass bottom and grown for 7 days to allow for the formation of EVs. Before adding IAs, cells were provided with
riboflavin-deficient medium for at least 48 h to avoid riboflavin autofluorescence. Then, cells were exposed to 5 mM of various IAs for 24 h at 37uC. (B)
Cells were pre-treated for one hour with FTC (10 mM) following co-incubation with C-1371 as in panel A. Control cells were cultured in FTC-free
medium in the presence of C-1371. Arrows indicate the localization of EVs that lack or contain IAs accumulation. (C) MCF-7 and MCF-7/MR cells were
exposed to various concentrations of C-1371 for 72 h in the presence or absence of FTC (10 mM), following which viable cell numbers were
determined. Shown are the means of three independent experiments, each performed in triplicates 6 SD. The IC50 values of C-1371 in MCF-7 and
MCF-7/MR cells were 4.360.1 and 27.863.7, respectively. Throughout the entire study, the bar denotes10 mm.
doi:10.1371/journal.pone.0035487.g001
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in nuclear fluorescence (Figure 5A and Movie S3). Similar
results were obtained when MCF-7/MR cells were exposed to the
non-ABCG2 substrate C-1375 (data not shown). Previously we
have shown that parental MCF-7 cells express little ABCG2 and
form much fewer EVs than does their MDR subline, MCF-7/MR
[8,10]. Incubation of MCF-7 cells with IAs which are either
ABCG2 substrates (Figure S2A, upper panel) or not (Figure
S2B) resulted in their dramatic accumulation in acidic lysosomes.
Photosensitization of these IAs-accumulating lysosomes resulted in
their lysis, consequent leakage of the drug to the cytoplasm and
gradual accumulation in the nuclei (Figure S2). In agreement
with this fluorescence microscopy analysis, we observed similar cell
sensitivity to C-1266 in MCF-7 and MCF-7/MR cells. Consistent
with the suggested lysosomal accumulation of IAs, inhibition of
ABCG2 transport function did not alter cellular sensitivity to C-
1266 in both of these cell lines (Figure 5B). Since MDR cells are
known to contain increased numbers of lysosomes per cell, we
studied lysosome numbers in parental and MDR cell lines; we
determined the number of lysosomes per cell in both MCF-7 and
MCF-7/MR cells using the well established viable lysosomal probe
Lysotracker red. This live staining revealed a ,2.5-fold increase in
lysosome number in MDR MCF-7/MR cells (3,9946754
fluorescence units/cell) relative to parental MCF-7 cells
(1,6506584 fluorescence units/cell). Thus, the increased number
of lysosomes in MDR MCF-7/MR cells would contribute to the
preferentially increased accumulation of IAs in lysosomes and
EVs, hence enhancing the selective photodestruction of MDR cells
when compared to normal cells.
Photoexcitation of IAs that accumulated in EVs markedly
increases the cytotoxic effect exerted by IAs
The results of the current study implied that upon illumination,
massive damage is inflicted to the EVs, the membrane of which is
shared by EVs-forming neighbor tumor cells. We therefore
explored the impact of such photosensitization on cell viability.
To this end, EVs-forming MCF-7/MR monolayers were first
exposed to a series of IAs that are ABCG2-substrates followed by
Figure 2. Photosensitization of C-1371-accumulating EVs results in destruction of EVs in MCF-7/MR cells. (A) MCF-7/MR cells were
grown as in Figure 1 legend and exposed to C-1371 (10 mM) for 24 h at 37uC to allow for its accumulation within EVs. Then, random fields were
photographed using a Zeiss inverted Cell-Observer microscope at an 6630 magnification. Next, these selected fields were continuously exposed to
blue light using the GFP+DsRED longpass filter (excitation 470627; emission 512620 and 630698) for 10 min and re-photographed using the same
parameters. Continuous arrows point at the location of EVs, whereas dashed arrows point at the nuclei of EVs-forming cells. (B) Following
illumination, cells were analyzed by Z-stack sections creating five 1 mm-thick optical slices. The black arrows point at the MSIS formed following
photosensitization.
doi:10.1371/journal.pone.0035487.g002
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ing an additional incubation for 48 h, cells were fixed with
methanol and stained with Crystal Violet to evaluate cell
morphology. Light microscopy revealed that the illuminated foci
of the monolayers were completely lysed and eradicated, thereby
forming blank areas with cell debris and residual cytoskeletal
structures surrounded by confluent unaffected monolayer cells that
were not illuminated (Figure 6A). Thus, cells that were not
exposed to light retained their intact morphology. Crystal Violet
staining of illuminated MCF-7/MR cells exposed to C-1266
(Figure 6A e and f) or parental MCF-7 cells exposed to C-1371
revealed similar results (Figure 6A g and h). However, in this
case, cell lysis occurred due to lysosomal photodestruction, thereby
leaving a symmetric round blank area with completely lysed cells,
thus reflecting the exact area exposed to light.
Based on these encouraging results we further hypothesized that
ABCG2- overexpressing MCF-7/MR cells may become highly
sensitive to the cytotoxic effect exerted by IAs upon illumination,
thereby resulting in reversal of MDR. To test this hypothesis, we
performed cytotoxicity assays in the absence or presence of
Figure 3. Immunofluorescence studies of ABCG2 and ZO-1 localization following illumination of C-1371-accumulating EVs formed
in MCF-7/MR cells. (A) A merged image of bright field and C-1371 green fluorescence in live MCF-7/MR cells before illumination. Immediately after
illumination, both the illuminated (B, C and D, a–d) and the non-illuminated (D, e–h) MCF-7/MR cells were fixed in 4% formaldehyde and co-reacted
with monoclonal antibodies to ABCG2 (BXP-53) and ZO-1. (B) Illuminated MCF-7/MR cells were stained with ZO-1 (green), ABCG2 (red) and DAPI
(blue), at a6630 magnification. (C)The bright field image underlines the structures of illuminated EVs. (D) An enlarged image of the area is indicated
by a white square in panel B. The green nuclear fluorescence in panel C is due to the intercalation of IA into DNA after the rupture of the membrane
of EVs due to photosensitization. C-1371-loaded, non-illuminated MCF-7/MR cells served as a control (e–h). Since immunofluorescent staining
includes membrane permeabilization, no accumulation of IAs was detected in EVs. Continuous arrows point at EVs whereas dashed arrows point at
the nuclei.
doi:10.1371/journal.pone.0035487.g003
Figure 4. Immunofluorescence studies of ERM and ABCG2 localization following illumination of C-1371-accumulating EVs formed
in MCF-7/MR cells. MCF-7/MR cells accumulating C-1371 (10 mM) were either illuminated (excitation 470627 emission 512620 and 630698) for
10 min at a6400 magnification to allow for photodestruction of EVs (A–D) or not illuminated (E–H). Cells were then immediately fixed and co-reacted
with monoclonal antibodies to ABCG2 (BXP-21) and ERM. The green nuclear staining in panel B is due to IA intercalation into nuclear DNA, following
EVs photodestruction. Continuous arrows point at EVs whereas dashed arrows point at nuclei.
doi:10.1371/journal.pone.0035487.g004
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either with C-1266 or C-1371 at a 3 mM concentration which
allows high rates of cell survival (C-1266 treatment: 7066.2% and
93.563% in parental and MCF-7/MR cells, respectively; C-1371
treatment: 7161.8% and 92.460.8% in parental and MCF-7/
MR cells, respectively) (Figure 6B and C). Remarkably, upon
illumination, the viability of MCF-7 and MCF-7/MR cells after
C-1266 treatment dropped to 19.6% and 12.8%, respectively.
Consistently, C-1371 displayed markedly decreased survival rates
of 25.6% and 53%, respectively.
Subcellular localization of topotecan in MDR cancer cells
versus drug-sensitive tumor cells and normal breast
epithelial cells
Our results indicated that IAs may readily accumulate in both
EVs via ABCG2-dependent concentration as well as in lysosomes
due to the hydrophobic weak base nature of IAs. To further
examine the selectivity of the drug treatment with IAs we searched
for photosensitive cytotoxic drugs that would localize exclusively in
ABCG2-rich EVs but not in lysosomes. In this respect, topotecan,
an established ABCG2 transport substrate [8,15,16,17], was highly
sequestered in EVs of MDR MCF-7/MR cells with no detectable
accumulation in lysosomes (Figure 7A). Consistently, no fluores-
cence signal of topotecan was detected in lysosomes or in nuclei of
parental MCF-7 cancer cells (Figure 7B). To address the
important issue of sub-cellular localization of topotecan in normal
breast epithelial cells, we used the non-transformed human
mammary epithelial cell line MCF-10A, which is widely used as
a normal counterpart of breast cancer cells [24,25,26]. MCF-10A
cells neither form tumors in nude mice nor colonies in soft agar-
based clonogenic assays. Similar to MCF-7 breast cancer cells, no
lysosomal accumulation of topotecan was observed in MCF-10A
cells (Figure 7C). Moreover, illumination of EVs which
accumulated topotecan resulted in the rupture of the EVs
membrane; this was followed by a gradual leakage of topotecan
from EVs to the cytoplasm of EVs-forming cells and its gradual
accumulation in nuclei (Figure 8 and Movie S4). The
photosensitizing capacity of topotecan was similar to the one
obtained with IAs (Figure 2 and Figure S1), albeit topotecan
Figure 5. Sub-cellular localization of IAs that are non-ABCG2 substrates and the impact of illumination on cell viability in C-1266-
accumulating cells. (A) MCF-7/MR cells were incubated with C-1266 (10 mM), which is not an ABCG2 transport substrate, for 5 h at 37uC (a–c).
Selected fields were continuously exposed to blue light for 1–2 min using the Cell-Observer microscope at a 6630 magnification (d–f). Continuous
arrows denote the location of EVs that are devoid of IAs (i.e. empty EVs), whereas dashed arrows point at the lysosomal or the nuclear localization of
C-1266. (B) MCF-7 and MCF-7/MR cells were exposed to various concentrations of C-1266 for 72 h in the presence or absence of Ko143 (0.7 mM),
following which viable cell numbers were determined. Shown are the means of three independent experiments, each performed in triplicates 6 SD.
doi:10.1371/journal.pone.0035487.g005
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effect, suggesting that topotecan was a less potent photosensitizer
than were the studied IAs.
Alkalinization of lysosomes using bafilomycin A1
abolishes lysosomal drug accumulation, but does not
affect drug accumulation in EVs
Applying a PDT approach using IAs which markedly
concentrate within lysosomes that undergo effective lysosomal
photodestruction might be toxic to normal tissues that surround
the malignant tumor. To further explore this drug treatment
selectivity, we postulated that the acidic pH of lysosomes is the
driving force for the marked lysosomal compartmentalization of
IAs. Hence, we used bafilomycin A1, a potent inhibitor of H
+-
ATPase (i.e. vesicular ATPase) to alkalinize lysosomal pH. MCF-
7/MR cells were incubated with C-1371 (10 mM), an established
ABCG2 transport substrate, for 24 h with or without pre-
incubation with bafilomycin A1 (100 nM). Consistent with our
previous findings, C-1371 highly accumulated in EVs due its
ABCG2-dependent concentration (Figure 9A a–d). Following
pre-incubation with bafilomycin A1, no lysosomal accumulation of
C-1371 was detected, whereas accumulation of C-1371 in EVs
was completely retained (Figure 9A e–h). Normal breast
epithelial MCF-10A cells were exposed to C-1371 (10 mM) for
5 h; expectedly, C-1371 readily accumulated in lysosomes and co-
localized with Lysotracker red (Figure 9B a–c). Pre-incubation of
MCF-10A cells with bafilomycin A1 resulted in the complete
elimination of the lysosomal signal as visualized by Lysotracker
red along with the complete disappearance of lysosomal
localization of C-1371 (Figure 9B d–f). MCF-7/MR
(Figure 9A i–l) and MCF-10A cells (Figure 9B g–i) incubated
solely with bafilomycin A1 served as positive controls to underline
the effect of bafilomycin A1. Hence, these results suggest that
lysosomal accumulation of IAs can be abolished by lysosomal
alkalinizing agents without compromising the marked accumula-
tion of the photosensitizer in EVs. The latter could be effectively
harnessed to selectively kill MDR cancer cells via photodestruction
of EVs without harming normal cells due to the lack of lysosomal
drug accumulation.
Figure 6. The effect of illumination on the viability and morphology of IAs-accumulating MCF-7 and MCF-7/MR monolayers. (A)
Confluent MCF-7/MR (a–f) and MCF-7 (g–h) monolayers were loaded with the indicated IAs (20 mM): 24 h incubation in the case of ABCG2-substrates
(i.e. C-1492 and C-1371), and 3 h incubation in the case of non-ABCG2 substrate C-1266. Then, cells were exposed to constant light: 10 min for
ABCG2-substrates (a–d) and 2 min for non-ABCG2 substrates (e–f) or while using MCF-7 cells (g–h). The illuminated foci were lysed thus appeared as
round, blank areas with cells debris and residual damaged cytoskeletal structures (see arrows). Cells that were not exposed to light surround the
illuminated areas and retained their intact morphology. Following illumination, cells were shifted to a fresh medium and incubated for an additional
48 h at 37uC. At the end of the incubation period, cells were fixed with methanol, stained with Crystal Violet, to improve visibility, and analyzed using
a Leica binocular under a66.4 magnification (a,c,e and g). Bar denotes 100 mm. Enlarged images of the areas indicated by a bold white square, on the
left column, were photographed at a 625.6 magnification and depicted on the right (b,d,f and h). Bar denotes 25 mm. Arrowheads point at the EVs
surrounded by cell debris. Confluent MCF-7 (B) and MCF-7/MR (C) monolayers were exposed to the indicated IAs (3 mM) for 72 h, following which
cells were exposed to 10 min illumination, whereas control cells were not. Then, growth inhibition was determined as detailed in Materials &
Methods.
doi:10.1371/journal.pone.0035487.g006
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In the current paper we describe a novel pharmacological
lethal Trojan horse strategy to differentially kill MDR breast
cancer cells via photoexcitation of photosensitizer anticancer
drugs that highly accumulated in ABCG2-rich EVs. Towards
this end, we provide several lines of evidence supporting the
conclusion that IAs which enter cells by diffusion, undergo a
dramatic compartmentalization within ABCG2-rich EVs in an
ABCG2-dependent manner, similarly to topotecan [8]. First,
hydroxyl group-containing IAs which proved to be bona fide
ABCG2 transport substrates [12], highly accumulated within
EVs. Consistently, the IAs C-1266 and C-1375, which lack a
hydroxyl group and thus are not ABCG2 transport substrates,
did not accumulate in EVs. Instead, as hydrophobic weak bases,
these IAs highly accumulated in acidic lysosomes presumably
due to irreversible protonation. Consistently, inhibition of
ABCG2 transport function by the specific transport inhibitor
Ko143 did not alter the cytotoxicity (IC50 values) of the non-
ABCG2 substrates C-1266 and C-1375 in both parental MCF-7
and MDR MCF-7/MR cells. Second, the accumulation of
hydroxyl group-containing IAs within EVs was completely
Figure 7. Topotecan accumulates exclusively in EVs formed in MDR cancer cells but not in the lysosomes of MCF-7 or MCF-10A
cells. MCF-7/MR (A), MCF-7 (B) and MCF-10A (C) cells were grown in 6-well dishes containing glass bottom in riboflavin-free medium for 5 days to
allow for EVs formation in MCF-7/MR cells. Then, cells were incubated with topotecan (1 mM for cancer cells or 0.5 mM for MCF-10A cells) for 24 h at
37uC. Lysotracker red DND99 (100 nM) was added for 1 h prior for cell imaging. Hoechst 33342 (2 mg/ml) was added immediately prior to microscopy
analysis and served to visualize nuclei. Cells were then photographed using the Cell-Observer microscope at a 6630 magnification. Bright field
images are presented for MCF-7/MR cells to better visualize the location of EVs (d and h A). Cells that were not exposed to topotecan served as a
negative control and underline the lysosomal pattern differences (e–h in A; d–f in B and C). Continuous arrows point at topotecan accumulated in EVs
(green), whereas dashed arrows point at the lysosomes (red).
doi:10.1371/journal.pone.0035487.g007
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mentalization within EVs of IAs which are ABCG2 transport
substrates, away from their intracellular targets, resulted in MDR.
Indeed, MCF-7/MR cells displayed 7-fold resistance to C-1371,
an ABCG2 transport substrate.
Taking advantage of the high level sequestration of these
photosensitizer IAs within EVs, we show here that upon
illumination, EVs underwent rapid lysis, thereby resulting in
selective killing of these MDR cells. Specifically, following
photosensitization, the membrane of EVs ruptured thus forming
multiple fragments of the EVs membrane; these fragments
immediately sealed and appeared as MSIS which appeared
entrapped within the lumen of the remaining cytoskeleton of
the highly damaged EVs. Consequently, no IAs-based green
fluorescence was retained in the lumen of these MSIS. These
results suggest that upon photosensitization, IAs-loaded EVs
release their IAs content due to the lysis of the EVs mem-
brane with consequent formation of MSIS. Moreover, it is highly
likely that the lumen of the EVs and MSIS is devoid of ATP,
hence excluding the possibility of residual functional ABCG2
activity.
We have previously shown that the formation of various ROS
upon illumination of IAs, is the underlying basis for IAs-dependent
cellular photodestruction [20]. We therefore propose here that the
cellular damage inflicted by illumination resulting in lysis of the
membranes of both IAs-loaded EVs and lysosomes and conse-
quent cell death is mediated by rapid production of ROS. This
conclusion is supported by the following line of evidence: first, in a
recent study we used established methodologies to show that
photoexcitation of various IAs results in the formation of ROS
including singlet oxygen and hydrogen peroxide [20]. Second, the
mediation of cell kill by ROS in our IA-loaded MDR cells
undergoing lysosomal photodestruction, is in accord with the
widely accepted mechanism of cytotoxicity of various photosen-
sitizers used in PDT including protoporphyrins; upon illumina-
tion, these photosensitizers undergo fluorescence excitation (i.e.
the triplet excited state), hence immediately transferring their
fluorescence (i.e. energy) to molecular oxygen, thereby resulting in
an instantaneous production of singlet oxygen and ROS. Recent
studies have determined that ROS production in a PDT scheme
using photoexcited protoporphyrin IX induced an essentially
instantaneous production of ROS with a remarkable time rate
constant of 0.0044 min
21 [27]. Thus, the rapid lysosomal
photodestruction in our MDR tumor cells here is consistent
with this rate constant of ROS generation. Singlet oxygen
radicals and ROS are extremely harmful to biomolecules as they
oxidize amino acids in proteins, polyunsaturated fatty acids in
lipids (i.e. lipid peroxidation), factors essential for enzymes,
thereby resulting in rapid cell death [28]. As such, upon
photoexcitation, the abrupt lysis of IAs-loaded EVs and lysosomes
is consistent with the rapid generation of ROS. Moreover,
illumination of EVs that are not containing photosensitizers
has no deleterious effect on cell morphology and viability, thus
the cytotoxic effect achieved is due to an intrinsic photosensitiz-
ing activity of IAs that highly accumulate in the lumen of ABCG2-
rich EVs.
In the absence of ATP-driven ABC transporters which
efficiently concentrate hydroxyl group-bearing IAs in EVs and in
the case of non-ABCG2 substrates, the organelles that predom-
inantly compartmentalized IAs were acidic lysosomes. Based on
the co-staining of IAs with the well established viable lysosomal
probe Lysotracker red, we found here that the subcellular
accumulation of IAs is similar to the well documented [29,30]
localization of hydrophobic weak base chemotherapeutics such as
anthracyclines, Vinca alkaloids and other cytotoxic agents including
acridone-based fluorescent compounds, the latter of which are
structurally related to IAs. Nevertheless, at higher concentrations,
IAs can also reach the nucleus where they readily bind DNA and
potently inhibit topoisomerase II activity [11]. Upon photoexci-
tation of IAs-loaded lysosomes, ROS formation occurs which
results in an instantaneous rupture of lysosomes and consequent
release of the highly acidic content of lysosomes including a wide
spectrum of destructive hydrolytic enzymes. Such lysosomal lysis
leads to rapid digestion of polypeptides and cytoskeletal structures,
nucleic acids and biomembranes and consequent cell lysis. This
conclusion is supported by the Crystal Violet staining of
monolayer cells undergoing photodestruction, which displayed
clear border between cell debris with residual cytoskeletal scaffolds
Figure 8. Photosensitization of topotecan-accumulating EVs results in destruction of EVs. MCF-7/MR cells were grown and treated as in
Figure 7 and random fields were photographed using the Cell-Observer microscope at a 6630 magnification (a–c). Next, these selected fields were
continuously exposed to blue light for 16 min and re-photographed using the same parameters (d–f). Lysosomes were detected using Lysotracker
red whereas nuclei were visualized using Hoechst 33342 staining. Continuous arrows point at the location of EVs and dashed arrows at lysosomes.
doi:10.1371/journal.pone.0035487.g008
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35487Figure 9. Treatment with bafilomycin A1 abolishes lysosomal accumulation of C-1371, but has no impact on its accumulation in
EVs. Cells were grown as described in Figure 7 legend. MCF-7/MR (A) and MCF-10A (B) cells were exposed to C-1371(10 mM) for 24 h or 5 h,
respectively, in the absence or presence of bafilomycin A. Lysosomes and nuclei were visualized as described in Figure 7 legend. Cells were then
photographed using the Cell-Observer microscope at an 6630 magnification. Cells exposed solely to bafilomycin A1 served as negative controls (i–l
in A; g–I in B). Continuous arrows point at the EVs accumulation of C-1371 (green), whereas the dashed arrows point at the lysosomes (red).
doi:10.1371/journal.pone.0035487.g009
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non-illuminated. Moreover, cytotoxicity studies revealed that
MDR MCF-7/MR cells became highly sensitive to the cytotoxic
effect exerted by IAs upon illumination, hence resulting in reversal
of MDR.
PDT acts directly on tumor cells typically via occlusion of the
vasculature that nourishes the tumor [31]. Treatment selectivity is
based on the accumulation of higher photosensitizer levels within
the target tumor than in the surrounding normal tissues. ABCG2
overexpression in the plasma membrane of malignant tumors that
mediates the extrusion of multiple anticancer drugs from the
tumor cells can decrease both the efficacy and selectivity of MDR
type drugs [31,32]. In contradistinction, ABCG2 overexpression
and its specific targeting to the EVs membrane of breast, lung and
hepatic epithelial malignant tissues allows for the high level
concentration of photosensitizer within EVs, thereby enhancing
the selectivity and efficacy of these PDT agents, as was shown here
by photosensitization of IAs- and topotecan-loaded EVs. Hence,
we propose five distinct mechanisms that support the specific
targeting of MDR cells via photodestruction of EVs and lysosomes
as a pharmacologically lethal Trojan horse approach: First,
ABCG2-rich EVs are present solely in MDR cells but not in
non-MDR cancer cells (e.g. MCF-7 cells) or in normal cells from
healthy tissues (e.g. MCF-10A). Second, the markedly increased
number of lysosomes in ABCG2-overexpressing MDR MCF-7/
MR cells and in various other MDR cancer cells relatively to their
drug naı ¨ve cancer cells as well as normal tissues, renders these
MDR cells much more vulnerable to lower light intensities due to
a substantial increase in lysosomal sequestration of photosensitiz-
ers. These decreased light intensities should be much less
deleterious to normal tissues that accumulate markedly less
photosensitizers. Third, the frequently increased acidity of
lysosomal pH in MDR cells along with the parallel alkalinization
of their cytoplasm [33,34,35] should further enhance the
differential photodestruction of MDR cells but not healthy
tissues. Forth, and perhaps most importantly, in order to maximize
the selectivity of the proposed PDT treatment one can rationally
select a photosensitizer that is an ABCG2 transport substrate but is
not a hydrophobic weak base, thus ruling out lysosomal drug
sequestration and subsequent lysosomal photodestruction upon
illumination of normal tissues surrounding the malignant tumor.
In this respect, we showed here that topotecan fulfilled the above
requirements; topotecan accumulated exclusively in EVs of MDR
cells but not in lysosomes of non-MDR cancer cells (MCF-7) or in
normal breast epithelial cells (MCF-10A) and effectively mediated
photodestruction of EVs. Fifth, an additional future approach to
improve treatment specificity is to combine hydrophobic weak
base photosensitizers and well tolerated lysosomal alkalinizing
agents such as bafilomycin A1. This drug combination treatment
allows for drug compartmentalization within EVs with no residual
lysosomal accumulation thus eliminating the lysosomal photo-
destruction route, thereby allowing for selective targeting of MDR
cancer cells.
In summary, targeting MDR cells via photodestruction of
EVs and lysosomes can be used as a selective pharmacologic
lethal Trojan horse approach to overcome MDR. A photosensi-
tizer can be rationally designed and/or chosen to accumulate
solely in EVs (e.g. topotecan), in lysosomes (IAs that are non-
ABCG2 transport substrates) or in both EVs and lysosomes (e.g.
IAs that are ABCG2 transport substrates). Further studies are
warranted to optimize the selectivity and applicability of such a
pharmacologic Trojan horse approach to selectively target and
eliminate MDR cancers while minimizing toxicity to normal
tissues.
Materials and Methods
Chemicals
Fumitremorgin C (FTC), mitoxantrone, topotecan, Hoechst
33342 and DAPI were purchased from Sigma-Aldrich (St. Louis,
MO). Lysotracker red DND99 was from Invitrogen (Carlsbad,
CA). Bafilomycin A1 was purchased from Enzo Life science.
Imidazoacridinones were synthesized by Prof. M. Cholody, B.
Horowska and M. Konieczny and kindly provided by Prof. A.
Skladanowski, Gdansk University, Gdansk, Poland.
Tissue culture
Human breast cancer MCF-7 cells [7], their mitoxantrone-
resistant subline MCF-7/MR as well as flavopiridol-resistant
MCF-7/FLV1000 cells were grown as previously described [8,10].
The immortalized, non-transformed human mammary epithelial
cell line MCF-10A, was grown in complete growth medium
composed of DMEM/F12 (Biological Industries, Beth-Haemek,
Israel) supplemented with 5% fetal calf serum (Invitrogen,
Carlsbad, CA), 10 mg/ml insulin (Biological Industries, Beth-
Haemek, Israel), 0.5 mg/ml hydrocortisone, 20 ng/ml epidermal
growth factor (EGF) and 100 ng/ml cholera toxin (Sigma, St.
Louis, MO), glutamine and antibiotics (Biological Industries, Beth-
Haemek, Israel). Prior to vesicular drug accumulation experi-
ments, cells were grown in custom-made riboflavin-deficient
RPMI-1640 medium (Biological Industries, Beth-Haemek, Israel)
supplemented with 10% dialyzed fetal calf serum (Invitrogen,
Carlsbad, CA), glutamine and antibiotics. All cell lines were grown
in a 5% CO2-humidified incubator at 37uC.
Live cell imaging
Cells were seeded in 24-wells plates on sterile glass coverslips
(5610
3cells/2 ml) or in dishes containing cover glass bottom
(2610
4cells/2 ml; World Precision Instruments) and grown in
riboflavin-free RPMI-1640 medium for at least 72 h prior to the
addition of drugs. Cells were then incubated with various IAs or
with topotecan for the indicated times at 37uC. In order to
alkalinize lysosomes, cells were pre-incubated with the H
+-ATPase
inhibitor bafilomycin A1 (100 nM) for 1 h followed by an
additional co-incubation with the indicated photosensitizer.
Lysotracker red DND99 (100 nM) was added 1 h prior to
microscope imaging to follow lysosomes in viable cells. Hoechst
33342 (2 mg/ml) served as a viable DNA dye to follow nuclei. In
all live imaging microscopy experiments, before analysis, cells were
washed thrice with PBS, resuspended in PBS supplemented with
1 mM CaCl2, 1 mM MgCl2 and 10 mM D-glucose. Then,
random colonies were analyzed using Zeiss inverted Cell-Observer
microscope, equipped with a CO2 and 37uC chamber, using the
following filters: phase mode, HE GFP (excitation and emission at
470640 and 525650 nm, respectively), GFP+DsRED longpass
filter (excitation 470627 and emission 512620 and 630698) or
DAPI mode (excitation and emission at 365 and 445650 nm,
respectively) at a magnification of 6400–6630. The merged
images were generated using the Cell-Observer software.
Photosensitization procedure
For drug accumulation experiments, different incubation times
were used i.e. 24 hours for intra-EVs accumulation versus 3–
5 hours for lysosomal accumulation. These incubation times were
selected as the experimentally proven minimal times necessary to
obtain optimal fluorescence intensity, which in turn is sufficient to
exert a cytotoxic effect following illumination. Drug-loaded cells
were washed with PBS, resuspended in PBS supplemented with
1 mM CaCl2, 1 mM MgCl2 and 10 mM D-glucose and
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were photosensitized using the Zeiss inverted Cell-Observer
microscope equipped with the GFP+DsRED longpass filter
(excitation 470627 and emission 512620 and 630698) at 6400
or 6630 magnification. The exposure to the constant blue light
was then imaged. In some cases the multiple snap-shots were
animated into a video using LSM image browser software (Zeiss
Inc.). Photodestruction of IAs-loaded EVs required a continuous
illumination for approximately 6–10 min. The different times
needed for photodestruction of different EVs were due to the
variable volume of EVs, drug concentration in the extracellular
medium and ABCG2 expression levels at the membrane of
individual EVs. Photodestruction of topotecan-loaded EVs
required longer illumination period of approximately 16 min.
Lysosomal photodestruction occurred rapidly, within a time frame
of 2–3 min. Longer exposure times to light had no additional
deleterious effect on cellular morphology or viability.
Immunofluorescence analysis
Cells were seeded on sterile glass coverslips in 24-well dishes
(5610
4cells/2 ml) in riboflavin-deficient medium and grown for 7
days at 37uC to allow for the formation of multiple EVs.
Immunofluorescence analysis was performed as previously de-
scribed [8]. Specifically, ABCG2 was visualized using either BXP-
21 or BXP-53 monoclonal antibodies (at 1:100 dilution, a
generous gift of Dr. G.L. Scheffer and Prof. R.J. Scheper),
followed by incubation with the secondary antibodies: FITC-
conjugated donkey anti-mouse IgG or rhodamine red-conjugated
donkey anti-rabbit antibody (1:100 dilution, Jackson ImmunoR-
esearch Laboratories, West Grove, PA), respectively. ZO-1 was
visualized using a mouse anti-ZO-1 monoclonal antibody (1:25
dilution, Invitrogen, Carlsbad, CA). The ERM protein complex
was visualized using rabbit monoclonal anti-ERM antibody (1:500
dilution, Epitomics, Burlingame, CA), which detects all three
ERM proteins. Cell nuclei were counterstained with the DNA dye
DAPI (0.5 mg/ml) during the incubation with the secondary
antibody. Samples were examined using Zeiss inverted Cell-
Observer. Merged images were obtained using the AxioVision
program (Zeiss, version 4.7).
Crystal Violet staining
Cells were grown to full confluence, exposed to 20 mM C-1266
for 2 h or to C-1371 and C-1492 for 24 h at 37uC and
photoexcited at random spots in the monolayer as described
above under ‘‘Photosensitization procedure’’. Cells were then
washed and resuspended with standard medium and incubated for
an additional 48 h at 37uC. At the end of incubation period, cells
were washed twice with PBS, fixed with 70% methanol for 1 min,
re-washed and stained with Crystal Violet (diluted 1:5, Merck).
The Crystal Violet dye served to obtain a contrast for better
visualization of cells and cell debris. This staining was executed by
applying the dye to the cells monolayer for approximately 1 min
following three washes with double distilled water. Then, cells
were dried and imaged using Leica M80 binocular (Leica
microsystem GmbH, Wetzlar, Germany) at the indicated
magnifications.
Cytotoxicity assays
The cytotoxic activity of antitumor agents was determined using
the colorimetric XTT cell proliferation kit (Biological Industries,
Beth-Haemek, Israel). Parental MCF-7 and MCF7/MR cells were
seeded (2610
3–5610
3 cells/well) in 96-wells plates and grown for
3 days to allow for the formation of EVs. Cells were then subjected
to increasing concentrations of IAs, incubated for 72 h in the
absence or presence of the ABCG2 transport inhibitors: FTC
(10 mM) or Ko143 (0.7 mM), following which viable cell numbers
were determined using the instructions of the manufacturer. To
determine the effect of illumination, IAs- treated cells were
photosensitized (excitation 470627 for 10 min) and incubated for
an additional 48 h prior to determination of growth inhibition
using the XTT assay. All experiments were performed in
riboflavin-deficient medium. Drug concentrations required to
inhibit cell growth by 50% (IC50) were determined and compared
between the cell lines. Drug resistance levels (fold) were calculated
by dividing the values of IC50 of MCF-7/MR cells by that of
parental MCF-7 cells or the IC50 of non-illuminated cells by that
of illuminated cells.
Supporting Information
Figure S1 IAs accumulation and photodestruction anal-
ysis in flavopiridol-resistant breast cancer MCF-7/
FLV1000 cells. (A) Merged image of fixed MCF-7/FLV1000
cells stained with monoclonal antibody to ABCG2 (BXP-21) and
DAPI. (B) Live MCF-7/FLV1000 cells were incubated with C-
1371 (10 mM) for 24 h at 37uC and illuminated for 10 min.
Continuous arrows denote the location of IAs in EVs, whereas
dashed arrows point at the nuclei. Immunofluorescence and live
cell analysis was performed using a Zeiss inverted Cell-Observer
microscope at a 6630 magnification.
(TIF)
Figure S2 In absence of EVs, both classes of IAs
accumulate in lysosomes which undergo rapid photo-
destruction upon illumination. (A) Parental MCF-7 cells
were grown in 6-well dishes containing glass bottom and exposed
to C-1371 (10 mM) for 2 h at 37uC. Lysotracker red DND99
(100 nM) was added for 1 h prior to fluorescence imaging. Cells
were then photographed using the Cell-Observer microscope at an
6630 magnification. Then selected fields were constantly
illuminated and photographed every second for a total duration
of 1–3 min using the same parameters. Continuous arrows point
at the C-1371 accumulating lysosomes, whereas the dashed arrows
point at the nuclei. (B) MCF-7 cells were grown, treated and
analyzed as in A, but exposed to C-1266. Shown is the localization
of C-1266 during the time course of illumination. Presented are
selected time points including 0, 30, 50 and 60 sec. Arrows denote
the dynamics of time-dependent lysosomal photodestruction.
(TIF)
Movie S1 Imaging of photodestruction of EVs and
gradual nuclear accumulation of C-1371 upon illumina-
tion of MCF-7/MR cells. MCF-7/MR cells were grown as
described in Figure 2 legend and exposed to C-1371 (10 mM) for
24 h at 37uC to allow for its accumulation within EVs. Then,
random fields were continuously exposed to blue light using the
GFP+DsRED longpass filter and photographed each 5 sec for 120
cycles (a total of 10 min) using the ted Cell-Observer microscope
at a 6630 magnification. The obtained time-lapse images were
animated into a video using LSM image browser software (Zeiss
Inc.).
(MOV)
Movie S2 Photodestruction of EVs and gradual nuclear
accumulation of C-1371 upon illumination of MCF-7/
FLV1000 cells. MCF-7/FLV1000 cells were exposed to C-1371
(10 mM) for 24 h at 37uC to allow for its accumulation within EVs.
Then, random fields were continuously exposed to blue light using
the GFP+DsRED longpass filter and photographed each 5 sec-
onds for a total of 120 cycles (a total of 10 min) using the Cell-
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time-lapse images were animated into a video using LSM image
browser software (Zeiss Inc.).
(MOV)
Movie S3 Lysosomal photodestruction and gradual
nuclear accumulation of C-1266 upon illumination.
MCF-7/MR cells were grown as in Figure 5 legend and exposed
to C-1266 (10 mM) for 5 h at 37uC. Then, random monolayer
fields were illuminated (excitation 470627 emission 512620 and
630698) for 1 min and photographed every sec using the Cell-
Observer microscope at a 6630 magnification. The obtained
time-lapse images were animated into a video using LSM image
browser software (Zeiss Inc.). Shown is an identical field to
Figure 5B.
(MOV)
Movie S4 EVs that accumulate topotecan undergo
photodestruction upon illumination of MCF-7/MR cells.
MCF-7/MR cells were grown and treated as described in Figure 8
legend. The continuous exposure to blue light using the
GFP+DsRED longpass filter was photographed each 5 sec for
200 cycles (a total of 16 min) using the Zeiss inverted Cell-
Observer microscope at a 6630 magnification. The obtained
time-lapse images were animated into a video using LSM image
browser software (Zeiss Inc.).
(MOV)
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